Study of Ivonescimab with TAS-102 for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your colorectal cancer is MSS or pMMR (a type of genetic testing).
- You have already tried at least two standard chemotherapy treatments for advanced colorectal cancer, and either the cancer continued to grow or you could not tolerate the side effects.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You feel well enough to be up and about (able to do light housework or office work) – ECOG 0 or 1.
- Your major organs (kidneys, liver, bone marrow) are working well enough, based on routine blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a targeted therapy) and alternating chemotherapy regimens as a first treatment for advanced colorectal cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
This trial is testing a new combination of drugs (ivonescimab and ADG126) given alone or with standard chemotherapy pills and IV therapy for people with advanced or metastatic colorectal cancer that is MSS (a subtype). The goal is to see if this approach works better for patients who have already tried certain chemotherapies.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Hear when a new MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.